Selpercatinib for Thyroid Cancer User Reviews
Brand names: Retevmo
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about selpercatinib
- Check interactions
- Compare alternatives
- Reviews (5)
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
"Diagnosed w/MTC 8/2020. Rx initiated 11/2020. One month later, primary nodule in thyroid and larger nodules in lung decreased in size by ~50%. Little or no reduction subsequently, but calcitonin and CEA continued to drop until in normal range (big drop first few months!). Started w/ 320mg, reduced after 3-4 months to 240mg, then to 160mg (80mg 2x daily). Condition stable as of 01/2023. Early side affects were abdominal pain and slight leg swelling in one leg. Pain went away after dosage reduced. Swelling diminished. Dr. says some from initial trial stable four years on. I can’t find any data, though, other than for trials that led to initial approval, which only refer to efficacy after 6 months. I wish I could find more new data, but am very happy with results to date, and I’m hoping stability continues … UNTIL A CURE IS FOUND! Keep working researchers. You don’t know us, but we’re counting on you. Thank you."